Table 2.
Treatment efficacy
| Outcome | All Patients (n=172) |
|---|---|
| Objective response rate, % (95% CI) | 32.6 (25.6–40.1) |
| Clinical benefit ratea, % (95% CI) | 41.9 (34.4–49.6) |
| Best overall responseb, No. (%) | |
| Complete response | 5 (2.9) |
| Partial response | 51 (29.7) |
| Stable disease | 65 (37.8) |
| Progressive disease | 35 (20.3) |
| Missing/Not evaluable | 16 (9.3) |
| Median time to event, months (95% CI) | |
| Duration of response | 13.1 (8.0–22.1) |
| Progression-free survival | 5.8 (5.4–7.6) |
| Overall survival | 17.6 (13.0–28.2) |
Abbreviations: CI, confidence interval.
a
CR + PR (of any duration) + SD (of ≥6 months).
*
Per investigator-assessment, required confirmation.